Literature DB >> 10235197

Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection.

C J McCarthy1, L J Crofford, J Greenson, J M Scheiman.   

Abstract

OBJECTIVE: Helicobacter pylori (H. pylori) causes chronic gastritis. The inducible prostaglandin synthetase cyclooxygenase 2 (COX-2) plays an important role in inflammatory conditions. We hypothesized that H. pylori-associated chronic gastritis would express COX-2 protein. Our aim was to evaluate the effect of eradication of H. pylori infection on COX-2 expression in the antral mucosa of patients before and after antibiotic therapy.
METHODS: Tissues were obtained from patients with non-ulcer dyspepia undergoing H. pylori eradication. Ten patients with proven H. pylori infection and subsequent successful eradication were studied. Three biopsies of antral mucosa were evaluated before and after H. pylori eradication. The amount of acute and chronic inflammation was quantitated. Immunohistochemical staining for COX-2 was expressed as a percentage of the total number of cells and correlated with the degree of chronic inflammation.
RESULTS: Specific immunostaining for COX-2 was observed in antral mucosa of patients infected with H. pylori. Patchy cytoplasmic staining was seen in surface epithelial cells and strong cytoplasmic staining for COX-2 was seen in parietal cells. Spotty cytoplasmic staining for COX-2 was also seen in lamina propria plasma cells, as well as there being macrophages present in the germinal centers of lymphoid aggregates. COX-2 expression could be detected both before and after eradication of H. pylori. The mean percentage of cells staining for COX-2 was significantly higher in H. pylori-infected mucosa, compared with mucosa after successful H. pylori eradication (33.4% +/- 5.4 vs 18.9% +/- 3.3, p = 0.038). COX-2 immunostaining correlated best with the chronic inflammation score (r2 = 0.78, p < 0.001). There was a strong correlation for those subjects who were H. pylori infected, as well as for those who had successful H. pylori eradication.
CONCLUSIONS: H. pylori associated acute and chronic antral inflammation was associated with immunohistochemical detection of COX-2 protein in epithelial cells, in addition to associated mononuclear cells and parietal cells. Expression was reduced, but not eliminated, in the epithelium after successful eradication of H. pylori. Despite the reduction in COX-2 expression after H. pylori eradication, expression of COX-2 in epithelial cells remained and strongly correlated with the extent of the chronic inflammatory cell infiltrate. The clinical implications of H. pylori-associated induction of COX-2 expression for patients on selective COX-2 inhibitors, in addition to the role of COX-2 in gastric carcinogenesis, deserve further study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235197     DOI: 10.1111/j.1572-0241.1999.01070.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  36 in total

1.  Association of haplotypes of inflammation-related genes with gastric preneoplastic lesions in African Americans and Caucasians.

Authors:  Jovanny Zabaleta; Maria C Camargo; Marylyn D Ritchie; Maria B Piazuelo; Rosa A Sierra; Stephen D Turner; Alberto Delgado; Elizabeth T H Fontham; Barbara G Schneider; Pelayo Correa; Augusto C Ochoa
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

2.  Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.

Authors:  Heng-Jun Gao; Lian-Zhen Yu; Jian-Feng Bai; Yan-Shen Peng; Gu Sun; Han-Lin Zhao; Kun Miu; Xiu-Zhen L ; Xiao-Yong Zhang; Zhi-Quan Zhao
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 3.  Helicobacter pylori eradication to prevent gastric cancer: underlying molecular and cellular mechanisms.

Authors:  Shingo Tsuji; Masahiko Tsujii; Hiroaki Murata; Tsutomu Nishida; Masato Komori; Masakazu Yasumaru; Shuji Ishii; Yoshiaki Sasayama; Sunao Kawano; Norio Hayashi
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

Review 4.  [Medicinal prevention of gastrointestinal tumors: aspirin, Helicobacter and more?].

Authors:  J C Becker; W Domschke; T Pohle
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

5.  Association of cyclooxygenase-2 expression with Hp-cagA infection in gastric cancer.

Authors:  Xiao-Lin Guo; Li-Er Wang; Shu-Yan Du; Chen-Ling Fan; Li Li; Peng Wang; Yuan Yuan
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

6.  Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis.

Authors:  Wei-Hao Sun; Qian Yu; Hong Shen; Xi-Long Ou; Da-Zhong Cao; Ting Yu; Cheng Qian; Feng Zhu; Yun-Liang Sun; Xi-Ling Fu; Han Su
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

7.  Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.

Authors:  J Labenz; A L Blum; W W Bolten; B Dragosics; W Rösch; M Stolte; H R Koelz
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

8.  The association between cagA+ H. pylori infection and distal gastric cancer: a proposed model.

Authors:  Mohammed S Al-Marhoon; Sheila Nunn; Roger W Soames
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

9.  Involvement of Ras and AP-1 in Helicobacter pylori-induced expression of COX-2 and iNOS in gastric epithelial AGS cells.

Authors:  Soon Ok Cho; Joo Weon Lim; Kyung Hwan Kim; Hyeyoung Kim
Journal:  Dig Dis Sci       Date:  2009-06-03       Impact factor: 3.199

10.  Cyclooxygenase-2 polymorphisms and the risk of gastric cancer in various degrees of relationship in the Chinese Han population.

Authors:  Yuchun Li; Liping Dai; Jianzhong Zhang; Peng Wang; Yurong Chai; Hua Ye; Jianying Zhang; Kaijuan Wang
Journal:  Oncol Lett       Date:  2011-09-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.